A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 29-35

  Green, M D ^a   Koelbl, H ^b   Baselga, J ^c   Galid, A ^d   Guillem, V ^e   Gascon, P ^f   Siena, S ^g   Lalisang, R I ^h   Samonigg, H ⁱ   Clemens, M R ^j   Zani, V ^k   Liang, B C ^k   Renwick, J ^k   Piccart, M J ^l   Yang, B B ^k   Bashir, S ^k   Hill, L R ^k   Breddy, J ^k   Foote, M A ^k   Ackland, S P ^aa   Andreesen, R ^m   Bashford, J ⁿ   Cascinu, S ^aa   Cocconi, G ^aa   Cocquyt, V ^o   Coleman, R E ^p   Dunlop, D ^q   Grothey, A ^b   Holmes, F A ^r   Koczwara, B ^s   Lind, M J ^t   Lluch, A ^u   Marques, F ^v   Miles, D ^w   Richardson, G E ^x   Santoro, A ^y   Schaafsma, M R ^z   more..

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Universitaetsklinik Frauenheilkunde   (Austria)

^e INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g OSPEDALE NIGUARDA CA GRANDA   (Italy)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ Medizinische Universitaetsklinik   (Austria)

^j Krankenanstalt Mutterhaus   (Germany)

^k AMGEN INC   (United States)

^l JULES BORDET INSTITUTE   (Belgium)

^m UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁿ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^o GHENT UNIVERSITY HOSPITAL   (Belgium)

^p WESTON PARK HOSPITAL   (United Kingdom)

^q GLASGOW ROYAL INFIRMARY   (United Kingdom)

^r TEXAS ONCOLOGY   (United States)

^s FLINDERS MEDICAL CENTRE   (Australia)

^t Princess Royal Hospital Hull   (United Kingdom)

^u HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^v HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^w GUY S HOSPITAL   (United Kingdom)

^x MONASH MEDICAL CENTRE   (Australia)

^y HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^z MEDISCH SPECTRUM TWENTE   (Netherlands)

^aa Medisch Spectrum Twente ^*

more..

Author keywords

Breast cancer; Clinical trial; Hemopoietic growth factor; Multicenter study; Neutropenia

Indexed keywords

DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; BRONCHOPNEUMONIA; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOXIA; INCIDENCE; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DOCUMENTATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THORAX PAIN; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME;

EID: 0037250159     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg019     Document Type: Article

References (16)

1. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
2. Gabrilove JL, Jakubowski A, Scher H et al. The effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-1422.
3. Morstyn G, Campbell L, Souza LM et al. Effects of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 667-672.
4. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-170.
5. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-324.
6. Blackwell S, Crawford J. Filgrastim (r-metHuG-CSF) in the chemotherapy setting. In Morstyn G, Dexter TM, Foote MA (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, NY: Marcel Dekker Inc. 1993; 103-116.
7. Welte K, Gabrilove J, Bronchud MH et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907-1929.
8. Molineux G, Kinstler O, Briddell B et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
9. Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989; 74: 1303-1307.
10. Roskos LK, Cheung EN, Vincent M et al. Pharmacology of filgrastim (r-metHuG-CSF). In Morstyn G, Dexter TM, Foote MA (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, NY: Marcel Dekker Inc. 1998; 51-71.
11. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9: 249-304.
12. Johnston E, Crawford J, Blackwell S et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
13. Holmes FA, Jones SE, O'Shaughnessy J et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
14. Heil G, Hoelzer D, Sanz MA et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710-4718.
15. Holmes FA, O'Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
16. Yang BB, Lum P, Renwick J et al. Pharmacokinetic rationale for a fixed-dose regimen of a sustained-duration form of filgrastim in cancer patients. Blood 2000; 96: 157b (Abstr 4384).